These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3421 related articles for article (PubMed ID: 7560451)
1. Differential cell- and immuno-biological properties of murine B16-F1 and F10 melanomas: oncogene c-fos expression, sensitivity to LAK cells and/or IL-2, and components of gangliosides. Nakayama J; Urabe K; Tsuchida T; Urabe A; Terao H; Taniguchi S; Hori Y J Dermatol; 1995 Aug; 22(8):549-59. PubMed ID: 7560451 [TBL] [Abstract][Full Text] [Related]
2. Different sensitivities of the murine melanomas BL-6 and BL-6-beta m to local injections of interleukin-2 (IL-2). Analysis of gangliosides after the treatment. Nakayama J; Tsuchida T; Toyofuku K; Shimokawa-Kuroki R; Taniguchi S; Hori Y Melanoma Res; 1994 Oct; 4(5):297-302. PubMed ID: 7858413 [TBL] [Abstract][Full Text] [Related]
3. Correlation of gangliosides GM2 and GM3 with metastatic potential to lungs of mouse B16 melanoma. Saha S; Mohanty KC J Exp Clin Cancer Res; 2003 Mar; 22(1):125-34. PubMed ID: 12725332 [TBL] [Abstract][Full Text] [Related]
4. Ganglioside GM2 expression on human melanoma cells correlates with sensitivity to lymphokine-activated killer cells. Hoon DS; Ando I; Sviland G; Tsuchida T; Okun E; Morton DL; Irie RF Int J Cancer; 1989 May; 43(5):857-62. PubMed ID: 2714890 [TBL] [Abstract][Full Text] [Related]
5. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases. Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L Cancer Res; 1995 Nov; 55(21):4941-9. PubMed ID: 7585534 [TBL] [Abstract][Full Text] [Related]
6. Suppression of B16 melanoma lung colonization by syngeneic monoclonal antibodies. Herd ZL Cancer Res; 1987 May; 47(10):2696-703. PubMed ID: 3552203 [TBL] [Abstract][Full Text] [Related]
7. Characterization of mouse melanoma cell lines by their mortal malignancy using an experimental metastatic model. Nakamura K; Yoshikawa N; Yamaguchi Y; Kagota S; Shinozuka K; Kunitomo M Life Sci; 2002 Jan; 70(7):791-8. PubMed ID: 11833741 [TBL] [Abstract][Full Text] [Related]
8. Sensitivity of B16 melanoma sublines to lymphokine-activated killer cells as determined by 51Cr-release and clonogenic assays. Tzeng JJ; Barth RF J Immunol Methods; 1990 Apr; 128(2):257-66. PubMed ID: 2324514 [TBL] [Abstract][Full Text] [Related]
9. Deficiency of ganglioside biosynthesis in metastatic human melanoma cells: relevance of CMP-NeuAc:LacCer alpha 2-3 sialyltransferase (GM3 synthase). Zebda N; Pedron S; Rebbaa A; Portoukalian J; Berthier-Vergnes O FEBS Lett; 1995 Apr; 362(2):161-4. PubMed ID: 7720864 [TBL] [Abstract][Full Text] [Related]
10. Responses of B16 melanoma cell lines, F1 and F10, to hyperthermia, lymphokine-activated killer cells and a combination of both in vitro. Nakayama J; Moroi Y; Toshitani A; Taniguchi S; Okamoto-Inoue M; Hori Y Br J Dermatol; 1992 Feb; 126(2):131-6. PubMed ID: 1536778 [TBL] [Abstract][Full Text] [Related]
11. Expression of the fos oncogene in B16 melanoma cells exhibiting different metastatic abilities. Urabe A; Nakayama J; Taniguchi S; Inoue M; Hori Y J Dermatol Sci; 1990 Nov; 1(6):455-8. PubMed ID: 2126954 [TBL] [Abstract][Full Text] [Related]
12. Ganglioside profiles of experimental melanomas and of their melanosomal fractions. Vedralová E; Borovanský J; Hach P Melanoma Res; 1995 Apr; 5(2):87-92. PubMed ID: 7620344 [TBL] [Abstract][Full Text] [Related]
13. Extraction of immunogenic and suppressogenic antigens from variants of B16 melanoma exhibiting low or high metastatic potentials. LeGrue SJ; Hearn DR Cancer Res; 1983 Nov; 43(11):5106-11. PubMed ID: 6616449 [TBL] [Abstract][Full Text] [Related]
14. Enhancement of metastatic potential of mouse B16-melanoma cells to lung after treatment with gangliosides of B-16-melanoma cells of higher metastatic potential to lung. Saha S; Mohanty KC Indian J Exp Biol; 2003 Nov; 41(11):1253-8. PubMed ID: 15332492 [TBL] [Abstract][Full Text] [Related]
15. Alteration of tumor phenotypes of B16 melanoma after genetic remodeling of the ganglioside profile. Tsurifune T; Ito T; Li XJ; Yamashiro S; Okada M; Kanematsu T; Shiku H; Furukawa K Int J Oncol; 2000 Jul; 17(1):159-65. PubMed ID: 10853034 [TBL] [Abstract][Full Text] [Related]
16. Gangliosides GM1, GM2 and GM3 inhibit the platelet-derived growth factor-induced signalling transduction pathway in vascular smooth muscle cells by different mechanisms. Sachinidis A; Kraus R; Seul C; Meyer zu Brickwedde MK; Schulte K; Ko Y; Hoppe J; Vetter H Eur J Cell Biol; 1996 Sep; 71(1):79-88. PubMed ID: 8884181 [TBL] [Abstract][Full Text] [Related]
17. Gangliosides enhance migration of mouse B16-melanoma cells through artificial basement membrane alone or in presence of laminin or fibronectin. Saha S; Mohanty KC; Mallick P Indian J Exp Biol; 2005 Dec; 43(12):1130-8. PubMed ID: 16359123 [TBL] [Abstract][Full Text] [Related]
18. Analysis of melanoma cells stably transfected with beta 1,4GalNAc transferase (GM2/GD2 synthase) cDNA: relative glycosyltransferase levels play a dominant role in determining ganglioside expression. Ruan S; Raj BK; Furukawa K; Lloyd KO Arch Biochem Biophys; 1995 Oct; 323(1):11-8. PubMed ID: 7487055 [TBL] [Abstract][Full Text] [Related]
19. Comparative study of sialidase activity and G(M3) content in B16 melanoma variants with different metastatic potential. Sawada M; Moriya S; Shineha R; Satomi S; Miyagi T Acta Biochim Pol; 1998; 45(2):343-9. PubMed ID: 9821865 [TBL] [Abstract][Full Text] [Related]
20. A purified GM3 ganglioside conjugated vaccine induces specific, adjuvant-dependent and non-transient antitumour activity against B16 mouse melanoma in vitro and in vivo. Carr A; Mazorra Z; Alonso DF; Mesa C; Valiente O; Gomez DE; Perez R; Fernandez LE Melanoma Res; 2001 Jun; 11(3):219-27. PubMed ID: 11468510 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]